The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 05, 1991
Filed:
Apr. 20, 1989
Other;
Abstract
A series of derivatives of the biologically active C-terminus of gastrin was synthesized to study the structural activity of the molecule and also to determine the smallest and highest affinity inhibitor of gastrin. Earlier work speculated that a peptide resistant to dipeptidase contained in a receptor would be an effective gastrin antagonist. Methods: Five dogs with both chronic gastric fistulae and Heidenhein pouches were used. After an 18 hour fast, gastric juice was collected both from the gastric fistula and pouch over 200 minutes at 10 minute intervals. MMC (Migrating Motor Complex) was monitored by a small balloon in the gastric antrum. Collections were initiated at the beginning of phase I of the MMC and were obtained under 3 conditions: Control, pentagastrin infusion (0.5 .mu.g/Kg/h, i.v.) and pentagastrin+peptide infusion (Indole propionic acid [IPA]- Leu-Asp-Phenethyl amine [PEA], Boc-Trp-Leu-.beta.Ala, IPA-Leu-.beta.Ala, or Boc-Trp-Leu-Asp-methyl meta Aminobenzoic acid {mABAOMe] at 20 pmol/kg/h for 70 min.). Pentagastrin infusion was started immediately before the next peak of the MMC. Peptides were infused 60 minutes after starting pentagastrin infusion. Results: All four peptides inhibited the stimulated acid secretion causing it to approach the control level.